The heat shock response was first identified in 1962 when Ritossa described the formation of chromosome puffs in the salivary glands of the fruitfly Drosophila bucksii subjected to temperature elevation, sodium salicylate or dinitrophenol (Ritossa, 1962) . However it was not until 1973 that Tissieres demonstrated that these 'puffing' patterns corresponded with the synthesis of a group of proteins, which he named the heat shock proteins (hsps) (Tissieres et al., 1974) .
Since then it has been demonstrated that many types of stresses can induce increased synthesis of these proteins resulting in them often being referred to as stress proteins. It has been shown that some of these proteins are constitutively expressed whereas others are inducible by stress; and that they play critical roles in the cell in the unstressed state. In particular, they function in chaperoning proteins of the cell ensuring that they are maintained in their correct state of folding under normal conditions (for review see Lindquist 1986 Lindquist , 1988 Creighton, 1990; Latchman, 1991) .
The hsps have been classified into families based upon their molecular weight (MW). In mammals these are hsplOO, hsp90, hsp70, hsp60, the 22-32 kDa hsps and ubiquitin which has a molecular weight of 7-8 kDa (Table I) .
Some members of the hsp70, hsp27 and hsp90 families have been suggested to play a defined role in cancer. The potential role of each of these hsps will be discussed with special reference to breast cancer where this role has been particularly studied.
Expression of hsps in breast cancer Hsp27 Hsp27 has been isolated by different laboratories as a 25 kDa protein associated with actin polymerisation, P24, an oestrogen-associated protein and as a 25 kDa growth-related protein (Ciocca et al., 1993a; Miron et al., 1991) . Hsp27 was initially identified as an oestrogen-binding protein in human breast cancer cell lines (Edwards et al., 1981) . Hsp27 expression has been studied extensively in breast carcinoma, where overexpression of hsp27 has been associated with shorter disease-free survival (DFS) in patients with local disease, although it does not provide prognostic value independent of other indicators such as the presence of disease that has spread to the lymph nodes (Thor et al., 1991) . Another study investigated immunohistochemical analysis of tumours in patients (n=361) with primary breast cancer in relation to disease-free survival, survival from first relapse and oestrogen and progesterone receptor status (Love and King, 1994) . Patients with tumours positive for hsp27 had a prolonged survival from first relapse but short DFS. This association with short DFS was only true in patients with no nodal involvement and agreed with data published elsewhere (Tandon et al., 1991) . Hsp27 has also been shown to predict for hormone sensitivity of advanced breast cancers (Love and King, 1994) .
There have also been several studies examining hsp27 expression and both drug and multidrug resistance in breast cancer cells (Oesterreich et al., 1993; Ciocca, 1992) . Transfections of breast cancer cells that usually have low levels of hsp27, with a full length hsp27 construct resulted in 3-fold elevated resistance to doxorubicin. When these cells were transfected with an anti-sense hsp27 construct, they were rendered sensitive to doxorubicin. It is possible the hsp functions to enable the cell to recover from damage induced by the drug, such as by interacting with proteins essential for the cell cycle.
It is of considerable interest to compare these data with those obtained in other tumour cell types. Thus hsp27 expression was studied in patients with neuroblastoma (n=53) and in 17 neuroblastoma cell lines to investigate the relationship between hsp27 expression, stage of disease and N-myc copy number (Ungar et al., 1994) . Increased hsp27 expression in neuroblastomas was associated with limited stage disease and inversely correlated with N-myc gene amplification, a feature known to predict poor clinical outcome. An inverse correlation was also observed between N-myc gene amplification and hsp27 protein levels among the neuroblastoma cell lines analysed. Immunohistochemical staining of sections of neuroblastomas showed that hsp27 was expressed most prominently in the cytoplasm of large ganglionic tumour cells present in neuronally differentiated areas of the tumours. Interestingly, differentiation of neuroblastoma cell lines using retinoic acid resulted in increased expression of hsp27. Retinoic acid decreases Nmyc expression and cellular proliferation (Thiele et al., 1985) . Thus, it is likely that there may be some interrelationship between N-myc and hsp27 protein levels and differentiation and proliferation status of neuroblastoma cells.
In malignant fibrous histocytoma, hsp27 expression is associated with longer survival (Tetu et al., 1992) . In addition, patients who developed metastatic disease were more likely to respond to chemotherapy if their tumours expressed hsp27. This contrasts to the in vitro data in breast cells which suggest that hsp27 expression is associated with resistance to chemotherapeutic drugs. Thus, high levels of hsp27 can be associated with both a good prognosis in some malignancies and a poor prognosis in others. (Davidoff et al., 1992) . Between 10 and 25% of patients with breast cancer have been reported as having circulating antibodies directed against p53 protein (Crawford et al., 1982; Vojtesek et al., 1995) . All antibody-eliciting tumours contained complexes between p53 and hsp70, which implies that hsp7o may be involved in the antigenic presentation of p53. These results suggest that mutant p53 protein which complexes with hsp70 in breast cancer induces a p53-specific humoral response. One possibility is that association of p53 with hsp70 in the tumour itself could present p53 to the immune system. In support of this a 70 kDa peptide-binding protein that is important in antigen processing and presentation has been shown to be hsp73. Additional evidence for the involvement of hsp70 in breast cancer arises from studies showing human tumour-infiltrating CD4+ T cells are able to react with B cells expressing hsp70 (Moshino et al., 1994) .
Hsp9O
The association of hsp90 and breast cancer is of considerable interest, following studies showing the association of hsp90 and steroid receptors (Pratt, 1987; Shyamala et al., 1989) .
Hsp9O exists as two isoforms, hsp90a and hsp9O# (also known as hsp89o and hsp89/3, sharing a high degree of homology. The expression of hsp89a has been investigated in human breast cancer tissue (Jameel et al., 1992 (Jameel et al., , 1993 . The authors isolated a cDNA clone, AJ1, by immunoscreening a human breast tumour library with a polyclonal anti-serum raised against breast cancer metastasis membranes. AJ1 showed complete homology with human hsp89a. The level of AJI was then studied in human benign breast tissue (n = 17), breast cancer (n = 143) and various breast cancer cell lines (n = 5). All tissues were found to have some expression of AJI but there were significantly higher amounts of AJI in malignant breast tissue compared with healthy breast tissue. No significant correlation was found between AJI expression and menopausal status, ER (oestrogen receptor) status, clinical or histological size or tumour grade. However, there was significant association between high AJI levels and histological node involvement. Short-term survival was increased in patients with low levels of AJ1, up to 11 years. AJ1 was also expressed constitutively in several breast cancer cell lines and also in a 'normal' breast cell line. Heat (Tsuboi et al., 1994; Ferrarini et al., 1992; Konno et al., 1989; Multhoff et al., 1995) . As there is no structural difference between the hsps in or on tumour cells and those expressed by normal cells the question is how these cytosolic proteins become expressed on the cell surface if they lack sequences for cell surface translocation. It is possible that anti-hsp antibodies crossreact with structurally similar epitopes on unrelated surface molecules; although several immunoprecipitation experiments suggest that the precipitated surface molecules are indeed hsps. Alternatively, hsps could be translocated to the cell surface by unknown mechanisms; hsp7o could be translocated passively by unrelated cell surface proteins. The localisation of hsp9o and hsp70 to the surface of tumour cells, in contrast to their normal intracellular location, suggests a role as markers of tumour cells. Another possibility is that they are released by adjacent dying cells and absorbed onto the surface of intact cells.
It has been demonstrated that inbred mice and rats immunised against their own tumours or tumours of the same genetic background become immune to challenges with tumour cells (Srivastava and Old, 1988 (Srivastava et al., 1986 (Srivastava et al., , 1993 Udono and Srivastava, 1993) . However, it appears not to be the hsp itself that causes this immune response, rather the peptides that are attached to it. This was demonstrated by the immunisation of mice with either hsp70 derived from MethA sarcoma or hsp70 purified from normal tissue. The tumour diameter in the mice immunised with MethA-derived hsp70 showed a considerable reduction unlike those in mice immunised with normal purified hsp70. However, when the MethA-derived hsp70 was purified using ATP affinity chromatography there was no reduction in the tumour, showing that it is the peptides that are responsible for this immune response rather than the hsp per se. Moreover, when the antigenically active MethA-derived hsp7o was further purified with ATP affinity chromatography the purified intact hsp70 remaining was no longer able to render the mice immune to subsequent challenges. Separation of the low molecular weight material showed a diverse range of peptides with molecular masses between 1000 and 5000 daltons. These results suggest that the antigenicity derives, not from hsp70 per se, but from associated peptides. The authors conclude that the peptides are derived from cellular proteins by proteolytic degradation. The authors postulate that the repertoire of peptides generated in the tumour cells is likely to differ from those generated in normal tissues because of tumour-associated mutations, which would explain the difference in antigenicity of tumour compared with normal tissue-derived hsp70. It is not clear whether the peptidebinding activity is found in all subsets of the hsp70 family.
Recently, there has been much evidence to indicate that hsp90, gp96 and hsp70 associate with antigenic peptides derived from cellular proteins. This has led to two hypotheses being proposed: (1) that hsps constitute a relay line in which the peptides, after generation in the cytoplasm by proteases, are transferred from one hsp to another, until they are finally accepted by MHC class 1 molecules in the endoplasmic reticulum; and (2) that the binding of peptides by hsps constitutes a key step in the priming of cytotoxic T lymphocytes (CTLs) in vivo. One possibility is the following: hsps are released from tumour cells in vivo during lysis of cells through infection or by the action of antibodies. The hsps which are now complexed with antigenic peptides derived from cognate cells are taken up by macrophages or other specialised antigen-presenting cells. The hsp-borne peptide is then routed to the endogenous presentation pathway in the antigen-presenting cell and is displayed in the context of that cell's MHC class 1, where it is finally recognised by the precursor CTLs. This mechanism explains the phenomenon of cross-priming and has implications for the development of immunological strategies against cancer.
Summary
It is clear therefore that hsps are overexpressed in patients with malignant tumours compared with healthy controls and this overexpression does show some correlation with disease features. Furthermore, expression of hsps has been reported on the cell surface of tumour cell lines. This could be associated with the immune response which has been reported with hsp90 and which also correlates with some disease features. It now appears that hsps may be involved in the presentation of tumour antigens leading to the possibility of hsps being used as a means of therapy. Hsp65 expression has not been investigated in patients with breast cancer.
However, transfection of bacterial hsp65 into a tumour cell line resulted in the hsp65-expressing tumour cells losing their tumongenicity in mice (Lukacs et al.. 1993) . Thus. hsps and the immune response to them are of interest as diagnostic and prognostic tools as well as a novel form of immunotherapy.
